An activatable near-infrared fluorescent probe for methylglyoxal imaging in Alzheimer's disease mice

Rational engineering of a recognition group to construct a two-photon reaction-based fluorescent probe for rapid and selective sensing of cysteine

It is highly required to rationally design fluorescent probes via a molecular engineering strategy with desired analytical performance for applications in sensing and imaging. Reaction-based fluorescent probes for highly selective sensing of cysteine (Cys) are mainly based on the participation of Cys in reactions such as, addition-cyclization with acrylates, cyclization with aldehydes, coordination displacement, Michael addition reactions, and cleavage reactions. Cys-triggered reactions with the O atoms of ether bonds has also been used to construct reaction-based fluorescent probes based on the substitution of the ether with the nucleophilic thiolate of Cys. However, many of the developed probes still suffer from long response times, interference from homocysteine (Hcy) and glutathione (GSH), high background fluorescence, and a lack of two-photon absorption (TPA) properties. Herein, we successfully design a Cys-sensitive two-photon fluorescent probe (F-BTD) using a donor-acceptor-donor (D-A-D) type π-extended benzothiadiazole framework as the fluorophore, with nitrobenzofuran (NBD) as the recognition unit. The proposed F-BTD probe displays some advantages over other probes including a rapid response time, high selectivity, low background fluorescence, and two-photon imaging capability. The F-BTD probe is applied to the two-photon fluorescence imaging of endogenous and exogenous Cys in HeLa cells with satisfactory results. For comparison, commonly used biothiol recognition groups including 2,4-dinitrobezensulfonyl and 2,4-dinitrophenyl are also used to construct S-BTD and N-BTD probes, respectively. The response mechanism of F-BTD to Cys is studied in detail through kinetic studies and transition-state analysis. This study may provide an example of how to design fluorescent probes with desired analytical performance by considering the recognition group as an important index of the design.

Fluorescent probes for sensing and visualizing methylglyoxal: progress, challenges, and perspectives

Methylglyoxal (MGO) plays an important role not only in physiological processes but also in pathological conditions, including diabetes, hypertension, and Alzheimer's disease. Therefore, developing accurate quantitative tools for MGO is of great significance for studying pathogenesis. Among the various methods available, the fluorescent probe method has garnered considerable attention due to its noninvasive detection capability, exceptional optical properties, good biocompatibility, and high sensitivity. In this review, we provide a brief overview of recent research on fluorescent probes used for MGO biosensing and bioimaging in living cells, tissues, and animals. Additionally, we summarize the advantages and existing challenges and also discuss future directions for development in this field.

A Mitochondria-Targeting Water-Soluble Fluorescent Probe for Selective Detection of Glyoxal in Living Cells

Glyoxal (GL) is a physiological reactive α-oxoaldehyde metabolite, produced by lipid peroxidation and autoxidation of glucose. In this work, a specific mitochondria-targeting fluorescent probe Z-GL for glyoxal has been developed by an introducing isopropyl group on the recognition site to tune the selectivity toward glyoxal. The probe showed high selectivity and sensitivity for glyoxal in an aqueous system. Importantly, the probe was able to visualize exogenous and endogenous glyoxal in living cells. Furthermore, the probe was mitochondria-targetable, and could be used for monitoring the level of intracellular glyoxal.

Selectively lighting up glyoxal in living cells using an o-phenylenediamine fused hemicyanine

Glyoxal (GL) is a reactive α-dicarbonyl compound generated from glycated proteins in the Maillard reaction. It has attracted particular attention over the past few years because of its possible clinical significance in chronic and age-related diseases. In this work, a reaction-based red emission fluorescent probe GL1 has been synthesized successfully by grafting an alkyl group onto an amino group to regulate its selectivity for GL. Under physiological conditions, the fluorescence intensity of GL1 at 640 nm obviously increased with the increase of GL concentration, and it exhibited high selectivity for GL over other reactive carbonyl compounds, as well as a lower detection limit (0.021 μM) and a larger Stokes shift (112 nm). At the same time, GL1 can selectively accumulate in mitochondria and can be used to detect exogenous and endogenous GL in living cells with low cytotoxicity.

A lysosome-targetable fluorescent probe for the ratiometric detection of formaldehyde in living cells and in vivo

Inspired by the synthetic method of benzoxazine derivatives and our previous research, a fluorescent probe (SWJT-6) was designed for formaldehyde (FA) detection based on the cyclization reaction. The synthetic SWJT-6 showed excellent colorimetric and ratiometric response to formaldehyde, and could be perfectly used as test strips to detect formaldehyde. It also showed a fast detection time (3 min), low detection limit (5.65 μM) and high selectivity for formaldehyde within various interfering analytes. In addition, SWJT-6 has been successfully applied in bioimaging of intracellular and lysosomal formaldehyde in both HeLa cells and zebrafish.

Emerging nanotechnology for Alzheimer's disease: From detection to treatment

Alzheimer's disease (AD), one of the most common chronic neurodegenerative diseases, is characterized by memory impairment, synaptic dysfunction, and character mutations. The pathological features of AD are Aβ accumulation, tau protein enrichment, oxidative stress, and immune inflammation. Since the pathogenesis of AD is complicated and ambiguous, it is still challenging to achieve early detection and timely treatment of AD. Due to the unique physical, electrical, magnetic, and optical properties of nanoparticles (NPs), nanotechnology has shown great potential for detecting and treating AD. This review provides an overview of the latest developments in AD detection via nanotechnology based on NPs with electrochemical sensing, optical sensing, and imaging techniques. Meanwhile, we highlight the important advances in nanotechnology-based AD treatment through targeting disease biomarkers, stem-cell therapy and immunotherapy. Furthermore, we summarize the current challenges and present a promising prospect for nanotechnology-based AD diagnosis and intervention.

Design of an activatable NIR-II nanoprobe for the in vivo elucidation of Alzheimer's disease-related variations in methylglyoxal concentrations

Clear elucidation of the changes in Alzheimer's disease (AD)-related methylglyoxal (MGO) levels in vivo is significant yet highly challenging. Fluorescence imaging in the second near-infrared region (NIR-II, 1000-1700 nm) has gained increasing attention as an observation method in living organisms, but an MGO-activatable fluorescent probe that emits in this region for in vivo brain imaging is lacking because of the existence of the blood-brain barrier (BBB). Herein, a biocompatible Fe3O4 nanoparticle (IONP)-conjugated MGO-activatable NIR-II fluorescent probe (MAM) modified with the peptide T7 (HAIYPRH) (named TM-IONP) is reported for the in situ detection of MGO in a transgenic AD mouse model. In this system, the T7 peptide enhances BBB crossing and brain accumulation by specifically targeting transferrin receptors on the BBB. Due to the MAM probe, TM-IONPs emit fluorescence in the NIR-II region and display high selectivity with an MGO detection limit of 72 nM and a 10-fold increase in the fluorescence signal. After intravenous administration, the TM-IONPs are easily delivered to the brain and pass through the BBB without intervention, and as a result, the brains of AD mice can be noninvasively imaged for the first time by the in situ detection of MGO with a 24.2-fold enhancement in NIR-II fluorescence intensity compared with wild-type mice. Thus, this MGO-activated NIR-II-emitting nanoprobe is potentially useful for early AD diagnosis in clinic.

Rapid sensing and imaging of methylglyoxal in living cells enabled by a near-infrared fluorescent probe

A novel near-infrared fluorescent probe (SWJT-2) has been designed and synthesized for the detection of methylglyoxal (MGO). It showed a low detection limit (0.32 μM), high selectivity and the fastest detection (15 min) over various reactive carbonyl compounds in aqueous solution. SWJT-2 had been successfully applied to bioimaging in HeLa cells to detect exogenous and endogenous MGO.

Mitochondria-targeted fluorescent probe for visualization of exogenous and endogenous methylglyoxal in living cells

An activatable mitochondria-targeted fluorescent probe Hcy-OPD was synthesized for the detection of methylglyoxal (MGO). For the introduction of a preorganized isopropylamino group on the aromatic o-diamine framework to regulate the hindrance effect, Hcy-OPD showed high selectivity and sensitivity (0.22 μM) for monitoring MGO. The probe can be applied successfully in the imaging of exogenous and endogenous MGO in living cells.

NIR-II imaging-guided diagnosis and evaluation of the therapeutic effect on acute alcoholic liver injury via a nanoprobe

Acute alcoholic liver injury (AALI) is hard to diagnose on account of no obvious clinical symptoms, and thereby it easily develops into serious liver diseases and threatens people's health. However, traditional methods for detecting AALI are far from satisfactory due to the low sensitivity, invasiveness and non-visualization, and the development of new techniques is in urgent demand. Near-infrared (NIR)-II fluorescence imaging has been widely studied in biochemistry and biomedicine. As the blood flow velocity of the liver is closely related to the progression of AALI, herein, a NIR-II fluorescent nanoprobe, NTPB-NPs, was applied to diagnose AALI by monitoring the fluorescence intensity changes in the liver caused by the variations of the blood flow velocity. More importantly, when medication was applied to alleviate the liver injury of AALI mice, NTPB-NPs could also track the therapeutic effect in situ. In this study, the relationship between hepatic vascular velocity and the progression of AALI was confirmed with NTPB-NPs via NIR-II imaging. To the best of our knowledge, this is the first time that a NIR-II fluorescence imaging technique has been used to diagnose AALI mice and evaluate the therapeutic effect on AALI mice. This study may also provide a potential NIR-II imaging agent for clinical research to improve the management of liver injury related diseases.

An anthracenecarboximide-guanidine fluorescent probe for selective detection of glyoxals under weak acidic conditions

An anthracenecarboximide-guanidine based turn-on fluorescent probe ANC-DCP-1 for selective detection of glyoxals (methylglyoxal and glyoxal, GOS) over formaldehyde under weak acidic conditions around pH 6.0 was reported. The probe showed great potential in studying relative GOS levels in weak acidic biological fluids such as in urine for diabetic diagnosis and prognosis, and also found application in the food industry such as for fast unique manuka factor (UMF) scale determination of Manuka honey.

Formation of 5-membered dihydroxyimidazolidines with increased deprotonation at around pH 6.0 and enhanced intramolecular charge transfer for turn-on fluorescence detection of glyoxals.

Activity-based fluorescent probes for sensing and imaging of Reactive Carbonyl species (RCSs)

This review explains various strategies for developing fluorescent probes to detect reactive carbonyl species (RCS). There are sevaral number of mono and diacarbonyls among 30 varieties of reactive carbonyl species (RCSs) so far discovered, which play pivotal roles in pathological processes such as cancer, neurodegenerative diseases, cardiovascular disease, renal failure, and diabetes mellitus. These RCSs play essential roles in maintaining ion channels regulation, cellular signaling pathways, and metabolisms. Among RCSs, Carbon moxide (CO) is also utilized for its cardioprotective, anti-inflammatory, and anti-apoptotic effects. Fluorescence-based non-invasive optical tools have come out as one of the promising methods for analyzing the concentrations and co-localizations of these small metabolites. There has been a tremendous eruption in developing fluorescent probes for selective detection of specific RCSs within cellular and aqueous environments due to its high sensitivity, high spatial and temporal resolution of fluorescence imaging. Fluorescence-based sensing mechanisms such as intramolecular charge transfer (ICT), photoinduced electron transfer (PeT), excited-state intramolecular proton transfer (ESIPT), and fluorescence resonance energy transfer (FRET) are described. In particular, probes for dicarbonyls such as methylglyoxal (MGO), malondialdehyde (MDA), along with monocarbonyls that include formaldehyde (FA), carbon monoxide (CO) and phosgene are discussed. One of the most exciting advances in this review is the summary of fluorescent probes of dicarbonyl compounds.

NIR-I fluorescence imaging tumorous methylglyoxal by an activatable nanoprobe based on peptide nanotubes by FRET process

Methylglyoxal (MGO), a glycolysis metabolite with high reactivity, can nonenzymatically modify proteins, lipids and nucleic acids etc., and it is closely related to the development of tumors. The accurate detection and high-performance optical imaging of MGO from deep tumor issues is of great significance for understanding their roles in tumor initiation and progression. Herein, we have presented a nanoprobe D/I-PNTs with emission in the first near infrared (NIR-I) region by employing a fluorescence resonance energy transfer (FRET) process between a far-red emission MGO probe and IR783 based on peptide nanotubes. The nanoplatform extended the emission range of MGO probe through FRET process and avoided complex molecular design and synthesis. The biocompatible peptide nanotubes improved the water solubility of MGO probe. D/I-PNTs was sensitive to MGO with a detection limit of 272 nM and enabled high-resolution NIR-I fluorescence imaging of MGO induced by glyoxalase I (GLO1) inhibitor in tumor with higher penetration depth (∼4 mm) than that in visible (Vis) region (∼3 mm). Most importantly, the FRET process based on the structure characteristics of peptide nanotubes can be a universal approach to realize the extension of emission wavelength and ratio detection of target analytes, which will be a promising strategy for bioimaging in deep tissue with high contrast.

A lysosome-targeting fluorescent probe to visualize endogenous and exogenous methylglyoxal in live cells and zebrafish

The first fluorescent probe targeting MGO in lysosomes was developed for the detection of intracellular and extracellular sources of methylglyoxal.

Dynamic evaluation of the protective effect of Dendrobium officinale polysaccharide on acute alcoholic liver injury mice in vitro and in vivo by NIR fluorescence imaging

Acute alcoholic liver injury (AALI) is a threat to human health. Dendrobium officinale polysaccharide (DOP) has the potential to protect the liver by enhancing the anti-oxidative system to maintain the relative balance of ROS (active oxygen species) and antioxidants in AALI mice. However, the dynamic improvement effect of DOP on AALI is still not clear and accurate medication guidance is not available, which limits the clinical application of DOP. Because of the advantages of high sensitivity, noninvasiveness, and visualization, near-infrared (NIR) fluorescence imaging has been widely studied in biochemistry and biomedicine. As the glutathione (GSH) level in the liver is closely related to the progression of AALI, herein, an NIR fluorescent probe for GSH, HCG was used to dynamically evaluate the effect of DOP on AALI mice. In this study, DOP was proven to maintain the relative balance of GSH content in the liver to protect it from damage. To the best of our knowledge, it is the first time to assess the effect of DOP on AALI mice through a NIR fluorescence imaging technique. This study may also provide a potential NIR imaging agent for the clinical research to improve the management of liver injury-related diseases.

Nitric Oxide Prodrug Delivery and Release Monitoring Based on a Galactose-Modified Multifunctional Nanoprobe

Nitric oxide (NO)-based cancer therapy has attracted much attention in recent years owing to its broad effects on cancer. Low concentrations of NO stimulate cancer cell progression, while its higher levels induce cell apoptosis, and thus, it has motivated the development of probes for in situ NO release monitoring. In this work, a galactose-modified benzothiadiazole-based fluorescent probe (GalNONP/C) was synthesized as both a NO-responsive nanoprobe and NO prodrug carrier. The probe exhibited far-red emission in the range from 550 to 800 nm, and the response showed acidity preference. The galactose on the probe enabled selective targeting of hepatocellular carcinoma (HCC) cells by binding to the asialoglycoprotein receptor (ASGPR) on the cell surface. The probe also delivered low-molecular weight NO prodrug JS-K into cells and monitored the real-time release of the generated NO. Furthermore, in vivo NO imaging with tumor targeting was demonstrated in HCC orthotopic transplantation nude mice and liver sections. Compared with the control experiment using a probe without NO prodrug loading, higher fluorescence response of NO was detected in the cell (3.0 times) and liver slices of the HCC tumor model (2.7 times). This strategy may pave the way to develop nanoprobes for in situ NO monitoring and therapy evaluation in NO-related cancer therapy.

Fluorescent Diagnostic Probes in Neurodegenerative Diseases

Neurodegenerative diseases are debilitating disorders that feature progressive and selective loss of function or structure of anatomically or physiologically associated neuronal systems. Both chronic and acute neurodegenerative diseases are associated with high morbidity and mortality along with the death of neurons in different areas of the brain; moreover, there are few or no effective curative therapy options for treating these disorders. There is an urgent need to diagnose neurodegenerative disease as early as possible, and to distinguish between different disorders with overlapping symptoms that will help to decide the best clinical treatment. Recently, in neurodegenerative disease research, fluorescent-probe-mediated biomarker visualization techniques have been gaining increasing attention for the early diagnosis of neurodegenerative diseases. A survey of fluorescent probes for sensing and imaging biomarkers of neurodegenerative diseases is provided. These imaging probes are categorized based on the different potential biomarkers of various neurodegenerative diseases, and their advantages and disadvantages are discussed. Guides to develop new sensing strategies, recognition mechanisms, as well as the ideal features to further improve neurodegenerative disease fluorescence imaging are also explored.